KNSA - CIK 0001730430
The table below shows Kiniksa Pharmaceuticals, Ltd.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $137.99M | $25.69M | $13.30M | $5.81M | -$126.30M | -$136.53M |
| Capital expenditure | $1.57M | $277.00K | $130.00K | $105.00K | $415.00K | $283.00K |
| Investing cash flow | -$188.99M | $37.67M | -$29.56M | -$8.08M | $128.63M | -$23.44M |
| Dividends paid | - | - | - | - | - |
Kiniksa Pharmaceuticals, Ltd. reported operating cash flow of $137.99M for fiscal year 2025. That is up 437.1% from $25.69M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$50.22M (FY 2017) to $137.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $33.02M | $12.27M | $1.50M | $2.52M | $5.88M | $227.09M |